Progress report: the National LF and STH programme in MYANMAR Dr. Ni Ni Aye, Program Manager (ELF) LF and STH program Mangers Meeting,Jakarta (23-24 sept,2014)

Slides:



Advertisements
Similar presentations
Module 2 Eligibility for a TAS TAS Global Programme to Eliminate Lymphatic Filariasis (GPELF) Training in monitoring and epidemiological assessment of.
Advertisements

Global Measles and Rubella Strategic Plan
Training in monitoring and epidemiological assessment of mass drug administration for eliminating lymphatic filariasis Module 1 Background.
Module 6 After the survey TAS Global Programme to Eliminate Lymphatic Filariasis (GPELF) Training in monitoring and epidemiological assessment of mass.
PROGRESS REPORT: The National STH Programme in BHUTAN Mr. Sangay Thinley 2014 RPRG Meeting Jakarta, Indonesia 23 – 24 Sept
Directorate of National Vector Borne Disease Control Programme Directorate General of Health Services Ministry of Health & Family Welfare, Delhi (India)
Private Sector Malaria Case Management: Experience from 7 years of implementation in Cambodia Presented by Dr. Socheat, Director of CNM RBM Working Group.
Malaria Elimination in Zanzibar. Introduction Dramatic declines in malaria morbidity and mortality over the last decade (prevalence remained
Module 3 Evaluation unit
Third Regional Workshop on Production and Use of Vital Statics: Applying Tools and Materials Available to Improve Vital Statistics (CRVS)
Country report-Tanzania Presented to EARN Annual Malaria Conference Kigali, Rwanda 15th –19 th November, 2004 NMCP.
Dr Ahmed Jamsheed Mohamed WHO South East Asia Regional Office 9-11 February 2015.
By Denis Kaffoko,(MSC.DE,B.STAT,PCGME) The effect of Scale up of TB-DOTS Services on Case Detections and Treatment success rates in Central Uganda.
Regional initiative to sustain country achievement SEAR Krongthong Thimasarn Regional Adviser, Malaria World Health Organization Regional Office for South-
Eliminating Lymphatic Filariasis in the Americas A Winnable Battle Center for Global Health Division of Parasitic Diseases and Malaria.
THE PRESENT EXPERIENCE AND CHALLENGES BEFORE THE BULGARIAN HEALTH INSURANCE SYSTEM IN THE FIELD OF HOSPITAL CARE Jeni Nacheva Director of Department for.
Global Measles and Rubella Management Meeting Progress and Challenges in Bangladesh March, 2011 Geneva, WHO HQ Dr Serguei Diorditsa.
Departmental Perspectives on Viral Hepatitis
Process of Development of Five Year Strategic Plan for Child Health Development Dr Myint Myint Than Deputy Director (WCHD) Department of Health.
One SADC, One Vision, One Way Working Together Towards MDG 6: SADC’s Common Vision Hon. Benedict Xaba, Minister of Health of Swaziland International AIDS.
Post-MDA surveillance ( including xeno-monitoring) Krishnamoorthy K. Vector Control Research Centre Pondicherry India.
GETTING READY FOR DUAL EMTCT VALIDATION IN THE AMERICAS Adele Schwartz Benzaken.
IMPLEMENTATION PLAN TO SCALE UP HIV/AIDS PREVENTION AND TREATMENT 1.
Trends in Morbidity for Lymphatic Filariasis in the Most Affected Area of Bangladesh Midori Morioka 1, Hossain Moazzem 2, Kazuhiko Moji 3, Yukiko Wagatsuma.
Lymphatic Filariasis By Morgan McBride.
Action Plan Good Health Situation of Population in Capital of Myanmar Yangon Division By DR MYA THIDA AYE.
INTEGRATED CONTROL OF NEGLECTED TROPICAL DISEASES (NTDs) IN UGANDA 1 Dr. Ambrose Onapa NTDCP/RTI (ENVISION)
Monitoring and Evaluation Module 12 – March 2010.
School-based deworming Challenges Collaborations Commitment.
Roadmap Progress Report 2011 Zambia SARN-RBM PARTNERS ANNUAL CONSULTATIVE MEETING, JULY 2011.
Models of Care for Paediatric HIV Miriam Chipimo MD MPH Reproductive Health & HIV&AIDS Manager, UNICEF, Malawi.
EPIDEMIOLOGY DENGUE, MALARIA Priority Areas for Planning Dengue Emergency Response 1. Establish a multisectoral dengue action committee.
Module 7 Verification of elmination TAS Global Programme to Eliminate Lymphatic Filariasis (GPELF) Training in monitoring and epidemiological assessment.
Assessing the Feasibility of Continuous Net Distribution in Kenya using Community Based Approach.
Indicators for ACSM.
Roadmap to Achieve RBM Targets September 2009 – December 2010 Ghana.
Global burden of LF Around 1.4 billion people in 73 countries at risk Over 120 million infected About 40 million disfigured and incapacitated.
Monitoring and Evaluation issues related to Preventive Chemotherapy (LF and STH) Dr. S. K. Jain Joint Director & Head Department of Parasitic Diseases.
Progress Report: National LF and STH Programme in Nepal
Progress report: the national LF and STH programme in Thailand By Sunsanee Rojanapanus, Dr. Thitima Wongsaroj 2014 RPRG Meeting WHO Region.
STRATEGIC PLAN & BUDGET PRESENTATION TO THE SELECT COMMITTEE DEPARTMENT OF HEALTH 6 APRIL 2005.
1 Roadmap to Achieve RBM Targets Country January 2011 – December 2011 Botswana.
NGO Involvement in the Improvement of Health Services in OIC Member Countries Brief Status of Muslim Aid.
Kenya Roadmap to Achieve RBM Targets September 2009 – December 2010.
Mohamed Faisal 2014 RPRG Meeting WHO Region.  Geography and Population ◦ Total population: 371,507 (Census 2006) ◦ Ecological zones – next slide  Political.
Working to overcome the global impact of neglected tropical diseases Documenting the achievement of elimination as a public health problem GPELF dossier.
Somalia 17 months Roadmap plan to achieve 100% coverage of malaria control by Dec Annual Malaria Revie and Planning Meeting FOR EAST & SOUTHERN AFRICA.
Strengthening SME system for national programmes from transmission reduction to elimination phase China Dr Li Xiao Hong National Program officer WHO, China.
IMPROVING ACCESS TO TREATMENT OF THE NTDS – CHALLENGES AND MEASURES Dr. Sultani Matendechero Head, Kenya National NTD Programme.
Joint application package (JAP)  Joint Application Package (JAP) was rolled out as an an integrated planning tool, rather than just an application form.
Progress Update of FY16 (Q1 + Jan 16) CAP-Malaria Burma 25 th Feb 2016.
ARV Treatment Scale Up: Progress in Ukraine Andriy Klepikov Executive Director, International HIV/AIDS Alliance in Ukraine ARV Treatment Scale Up: Progress.
2007 Pan American Health Organization 2004 Pan American Health Organization Malaria in the Americas: Progress, Challenges, Strategies and Main Activities.
Stop TB in China Challenges, Constraints & Actions Dr Wang Longde Vice Minister of Health China 24 March 2004.
Thailand experience in implementing collaborative HIV/TB activities Anupong Chitwarakorn, MD Ministry of Public Health, Thailand TB/HIV Satellite symposium.
HIV/AIDS Epidemic in India Trends, Lessons, Challenges & Opportunities
A Workshop for Data Entry Clerks
Dr. Upendo John Mwingira NTD programme manager
TB- HIV Collaborative activities in Romania- may 2006 status
Malaria Elimination Programme Timor Leste
Strategic Plan & Budget Presentation To The Portfolio Committee
Review of integrated PSM resources and tools and introduction to group work Upjeet Chandan ICCM FTT 17th February 2016.
Role of Health Institutions in Vital Registration
APPMG December 17, 2008 Presented by Dr. John P. Rumunu (MPH, MB.BS)
Data Collection/Cleaning/Quality Processes MISAU Experience in Mozambique September 2017.
Update on Global Fund ATM
Mectizan Donation for IDA countries
Roles of District Community-Directed Intervention (CDI) Team Members
The Global Fund to Fight AIDS, Tuberculosis and Malaria
RTI International Daniel A. Cohn Sr Technical Advisor
Presentation transcript:

Progress report: the National LF and STH programme in MYANMAR Dr. Ni Ni Aye, Program Manager (ELF) LF and STH program Mangers Meeting,Jakarta (23-24 sept,2014)

Background Information Geography and Population – Total population – (2014 Census) – Ecological zones - Myanmar,the largest country in mainland in South East Asia with a total land area of 676,578 square kilometer Political & Health Administrative Divisions: -First level (7 States and 7 Regions) -Second level (69 Districts, 330 townships, 82 sub townships and 396 towns) -Third level (3045 wards, village tracts and Villages)

Historical Perspective First case of elephantiasis -Indian man, Thayet tsp Dr Nandy, a surgeon of RGH – found out the relation between hydrocoele and presence of Mf 1959, Municipal Council of Rangoon - Anti- filarial campaign - vector control Division of Health Dep; - NMBS & treatment of (+)ve cases , Filariasis Research project (WHO)in Rangoon Pilot vector control programme - using 50% EC fenthion larvicide in 16 tsp; of Rangoon by health department (D.O.H )Directorate of Health - Filariasis control project -

Historical Perspective (Cont;) integrated with Malaria, DHF and J-B Encephalitis control Programme into VBDC Program 1983, Culex larval control was stopped because of vector resistant to insecticide, although case finding with NMBS and treatment of positive cases , the Global Strategy for Elimination of Lymphatic Filariasis (ELF) has been adopted.

National programme overview IndicatorLFSTH Year of inception of the national programme Target date for elimination2020 Name of administrative unit for implementation of PC District Total # administrative units requiring PC at the start of the programme 4567 Total population requiring PC in the country Total pop in endemic IUs (40,014,402) Sum of preSAC & SAC requiring PC (14,634,198)

PC Programme Financing Contributors to the 2013 programme costs (and rough estimate of contributions by each if available): ContributorFunding (US$) National governmentTravel allowance Sub-national governmentTransport cost for drug Internal donors External donors (GNNTD)27000 Others (WHO)7500 Others (JICA)IEC

PC programme achievements 2013 IndicatorTargetedAchieved M&E Total # sentinel and spot check sites surveyed (LF) 13 Total # sentinel sites surveyed (STH) 80 Total # IUs where stopping-MDA TAS implemented (LF) 00 Total # IUs which passed TAS and stopped MDA (LF) 00 Total # IUs where surveillance TAS implemented (LF) 30 MMDP # IUs where hydrocele surgeries performed 65 # IUs where lymphedema and ADLA management provided 45 Activities TargetedAchieved # administrative units for PC # people # administrative units for PC # people PC MDA2 (DEC + ALB) T3 (ALB/MBD) for STH 1 st round T3 (ALB/MBD) for STH 2 nd round

Progress Towards LF Elimination Definitions Started MDA≥5 MDA roundsSurveillanceMMDP access

Progress Towards LF Elimination

Progress Towards STH scale up *Coverage =

Progress Towards STH scale up *Coverage =

PC coverage, 2013 *65% for LF and 75% for STH **reported coverage was verified by coverage survey or similar independent activity PC type # administrative units receiving PC # administrative units with reported coverage above target* # administrative units where coverage was verified** MDA2 (DEC + ALB) 36 T3 (ALB/MBD) for STH 1 st round 67 T3 (ALB/MBD) for STH 2 nd round 67

Impacts of MDA in Sentinel Sites (LF) # SS/SC sites Sentinel Sites <1% mf Sentinel Sites ≥1% mf Spot Check sites <1% mf Spot Check sites ≥1% mf Baseline surveys Latest surveys (post-MDA)

PC Monitoring and Evaluation Describe how coverage is monitored Post MDA survey, Area coverage survey, Pop coverage

SAE protocol (Severely affected Event) Detection, Management, Reporting For <5 children and the ones who has problem to swallow the drug - Tablets should be crushed and given with sufficient water to prevent choking To exclude those people - who were taking other drugs for treatment of other diseases from MDA - who were suffering from other chronic diseases like, TB, Hypertension, Heart / renal / liver diseases (with evidence of taking treatment from any health facility) - who were ill or bed ridden during the time of MDA - < 2 year age group and pregnant women from MDA

# # administrative units currently eligible for surveys to stop mass treatment5 # administrative units where surveys to stop mass treatment were conducted 0 # administrative units where criteria was passed and mass treatment stopped Justification for stopping MDA without TAS in the above IU s Integrated assessment of STH considered? LF Transmission Assessment Survey to stop MDA

LF Transmission Assessment: Forecasting Year Number of IUs to be covered TAS1 TAS2 TAS3 Total number of EUs ICT/LF ST Required* * * * * * * *24 *sum of the total sample size required for each EU assessed;

Integrated Vector Management (LF) Describe any activities targeted to control LF vectors (including those conducted by other programmes) Training, Entomology survey (Malaria,JE and DHF) Describe monitoring and evaluation of such activities

LF MMDP – Strategy LF National policy exist?Morbidity Mx as in strategy Organizational placement within the government (who is responsible?) National ELF program PM is responsible How integrated with the health service?National LF programme and Public health division at various level Training of service providers conducted (by who? How frequent?) RO and TL from Reginal VBDC team are already trained and they give training to VBDC staff and BHS annually before MDA conduct. Patient mobilization and registration (by who? How?) VBDC staff register patient who come to VBDC clinic

LF MMDP – monitoring and evaluation LF Describe how MMDP services are currently monitored and reported to the national programme Monitored at regional level and reported to National program,but it need to be strengthen How is “access” determined?Determined by Regional RO and TL as clinically and also mf positive cases. Is there any quality assessment of provided services? Not yet, need to be done quality assessment

Best Practices Describe interventions and/or M&E activities that worked well i.Integrated activities with STH program,Nutrition program,Basic Health under umbrella of DOH ii.Disease-specific activities – as VBDC include malaria,DHF,Chikungunya and JE diseases, So that manpower work together for all diseases. iii.Voluntarily participated – VHW as drug distributors are voluntarily participate and BHS monitor them at grass root level iv.In spite of no incentives- incentive like materials can not be given since MDA was conducted, most of VHW are still participating during MDA. It is most important weakness to raise drug coverage. It must be fulfil by all partners as well as by goverment.

Issue and Challenges during the preparation of MDA in 2013 Micro-planning- Region and State,Township population register were distributed all Tsps,but it were not enough and copied during population data collection Due to planned for MDA in 2012 training for TMO and SMO and VBDC staff were trained since early month of 2012, but late arrival of DEC,we could not conduct MDA in 2012 BHS guide line for MDA were distributed to all BHS before MDA start Some of the trained TMO and BHS transfer to non LF endemic township

Issue and Challenges during the preparation of MDA in 2013 distribution of drug and IEC and arrived to RHC before MDA started Transportation cost of Drug and IEC were borne by ELF porgram with the support of GNNTD, WHO and government Drug distribution Team were not well formed in some of the township both existing and New IU Distribution of pamphlet were not received by each household before MDA Advoccay on MDA at central,State/region and township level

Issue and Challenges during MDA in 2013 No death due to drug, only one child death due to chocking of drug in 2013 Deaths case were reported during MDA are co incidental death during MDA conducted Most s/e are Dizziness, Head ache,vomiting MDA was implemented during I week without discontinuation even rumors on MDA Although some of township has low population coverage of ingestion of drug,more than 65 % of coverage was achieve in district

During the implementation of MDA Drug distributers team could not explain about drug and about LF to household member. They left drug for some person who were not at home and they marked as ingested drug People were not ready to ingest drug because they did not know that drug distributor will come and people refused to ingest when they heard rumors on SE of drug starting 2days of implementation weak supervision and monitoring during MDA by central, Regional and state,even in Township level

after the implementation of MDA Post MDA survey were mainly done by central and some TMOs But weak supervision and monitoring post/after MDA by central, Regional and state,even in Township level Post MDA survey did not conduct in every township Still rumors came out even after the MDA was finished in some state and Region especially Thai border

Out of 45 Endemic Districts (IU), Myanmar has covered 43 IU from Within 13 years, 3 IUs have reached the elimination target, Now 36 out of 43 IU was conducted in 2013 only new 21 district could be started MDA in 2013 (2 IU from Kachin state left) Total pop 35.3 M were covered,85% of total pop,90.9 % of eligible pop in 2013 Previously the main threat of the program is availability of DEC and late arrival of DEC. Integrated NTD of Joint request for Preventive chemotherapy, it will be regular availability of drug of LF and STH Issues and challenges

Availability of resources Now DEC tablets are donated through WHO & Albendazole is donated by the GSK company, IUs of high baseline Mf rate may need more rounds of MDA which in turn need more resource WHO ( )RB –10800 USD only No external or internal financial support previously Funding from GNNTD support US$ for operational cost in 2011,27000 US$ will support for operational cost for implementation of MDA (2013) Government support – in terms of staff, salary, traveling allowances, warehouses, transportation cost at township level and provision of IEC,training cost for BHS and VHW will be supported in 2014 ( request budget for MDA to government- 400,000 USD CNTD will support for TAS in 2014 and find to continue support for more activities.

ActivitiesYear 1Year 2Year 3Year 4Year 55-Year Total Coordination and training$702,240$350,000 $2,102,240 Mapping$0 Drug distribution$263,000 $1,315,000 Social mobilization$199,030 $995,150 Monitoring and evaluation$328,636$60,836$417,636$19,136$680,636$1,506,880 Morbidity control$10,500$3,500 $24,500 Total (USD)$1,503,406$876,366$1,233,166$834,666$1,496,166$5,943,770 Budget for NTD control and elimination in Myanmar ( ) 30 Myanmar’s national NTD program aims to treat 41 million people for at least one NTD at an estimated cost of less than US$0.04 per person per year, underscoring the cost-effectiveness of NTD control and elimination programs.

Programme Plan Activities 2014 target2015 target # administrative units for PC # people # administrative units for PC # people PC MDA2 (DEC + ALB) M T3 (ALB/MBD) for STH 1 st round T3 (ALB/MBD) for STH 2 nd round Activities2014 Target2015 Target M&E # districts/IUs where coverage surveys are planned for any PC diseases 36 IU/205 tsp40 # IUs where pre-TAS sentinel site and spot checks planned (LF) 6 IU12 # IUs where TAS for stopping MDA is planned (LF)5 IU10 # IUs where STH survey integrated with LF TAS planned # IUs where MMDP is to be evaluated (LF)2IU10 IU # IUs where surveillance activities are to be carried out (LF) 3 IU5 IU MMDP# IUs where MMDP services newly initiated (LF)10 IU IVM# IUs where IVM coordinated to target LF vectors10IU

PC medicine request for 2015 ALB (LF)ALB (STH)MBDDEC required in stock in pipeline requested to WHO requested to MDP (IVM) or ITI (AZI) Procured from other sources (source, # tablets and target age group)

Thank You for Attention